MCKESSON CORP
NYSE: MCK·Irving, Texas·CIK 0000927653
- Price
- $1,105.04
- Base IV
- $1,149.07
Valuation snapshot
At $1,105.04, the price sits between our bear case ($764.42) and base case ($1,149.07).
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $1,149.07
- above today's price · range $764.42–$1,684.78
- Price vs base case
- 4% below
- $1,105.04 against $1,149.07
- Base case · our researched forecast, 2026-11-06See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
The price has risen 3.1% since this valuation was struck on 2026-11-06, so some of the gap opened up after these figures were set.
Whisker on the base case runs bear $764.42 to bull $1,684.78. Values per share.
Price against each value
- Bear case
- $764.42
- Price 45% above
- No growth
- …
- —
- Base case
- $1,149.07
- Price 4% below
What does Mckesson do?
McKesson distributes pharmaceuticals, medical-surgical supplies, and laboratory equipment while providing technology and logistics services to pharmacies, healthcare providers, and hospitals.
It brought in $418.8B of sales in the 12 months to Sep 2026.
- Industry
- Industrials
- Based in
- Irving, Texas
- Trades on
- NYSE as MCK
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 1¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 96¢ of every dollar.
- Making what it sells96¢
- Sales, marketing and admin2¢
- Left as profit1¢
Who pays Mckesson, and for what?
McKesson distributes medicines and medical supplies and provides services and technology to pharmacies, healthcare providers, and drug companies. It earns revenue from product distribution and from services such as oncology practice support, medication access technology, and logistics.
Its customers include pharmacies, hospitals, clinics, other healthcare providers, pharmaceutical companies, payors, and government entities.
North American Pharmaceutical
84%Distributes medicines and related products in the U.S. and Canada, and provides pharmacy and healthcare services.
Oncology & Multispecialty
12%Provides specialty drug distribution, oncology and other specialty practice support, infusion services, research, and related technology.
iKnowMed oncology EHR clinical decision supportImage: Ontada Medical-Surgical Solutions
3%Distributes medical and laboratory supplies and provides logistics and related services to U.S. providers, mainly outside acute-care hospitals.
Prescription Technology Solutions
1%Provides technology and services connecting patients, pharmacies, providers, health plans, and drug companies to support medication access and affordability.
Other
0%Includes the former Norwegian operations, which McKesson sold during fiscal 2026.
Where its work physically happens, beyond headquarters:
- Jeffersonville pharmaceutical distribution center — Jeffersonville, United States. This automated distribution center supports pharmaceutical order fulfillment in McKesson’s largest revenue segment.
- Clermont specialty distribution center — Shepherdsville, United States. Its automated operations fulfill plasma, biologics, and other specialty-drug orders, supporting capacity in a growing product category.
- CoverMyMeds Columbus hub — Columbus, United States. The hub houses CoverMyMeds teams developing medication access and affordability technology for McKesson’s Prescription Technology Solutions business.
- McKesson Canada head office — Saint-Laurent, Canada. This office is McKesson Canada’s principal business hub for its Canadian operations.
- McKesson Medical-Surgical Richmond office — Richmond, United States. The office supports the Medical-Surgical Solutions business, which reported $11.5 billion in fiscal 2026 revenue and is being prepared for separation.
How is the business doing?
Sales grew from $238.2B in 2021 to $403.4B in 2026, about 11% a year.
Running the business leaves about 2¢ of each sales dollar as operating profit, up from 2¢ in 2021.
After paying for its upkeep and new investment, it had $7.1B of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
McKesson says its mission is to improve care in every setting, one product, one partner, and one patient at a time.
“To improve care in every setting — one product, one partner, one patient at a time”
What management says it is working on now:
Grow oncology and specialty care
Management highlights expanding support for oncology and specialty providers, including practice management and specialty medicines.
McKesson Reports Fiscal 2026 Fourth Quarter and Full Year ResultsImprove medication access through biopharma services
Management says it is accelerating patient access through its biopharma support services and technology platform.
McKesson Reports Fiscal 2026 Fourth Quarter and Full Year ResultsSeparate Medical-Surgical Solutions
McKesson is preparing the segment to become an independent company; the separation depends on regulatory, tax, and other conditions.
McKesson Corporation 2026 Form 10-KImprove operating efficiency and technology
Management is pursuing cost and process changes, including a Prescription Technology Solutions efficiency program expected to run through fiscal 2029.
McKesson Corporation 2026 Form 10-KStrengthen North American distribution
Management cited the core distribution businesses and specialty growth as important sources of momentum in its latest quarterly update.
McKesson Reports Fiscal 2027 First Quarter Results
- Adjusted earnings per diluted share, Fiscal 2027
- $44.20 to $45.00
- McKesson Reports Fiscal 2027 First Quarter Results
- Adjusted earnings per diluted share growth, Long term
- 13% to 16%
- McKesson Reports Fiscal 2026 Fourth Quarter and Full Year Results
What's changing right now?
Growth is holding steady. In Q2 2027 it sold 8% more than a year earlier. The year before, quarters averaged 9%.
Its operating margin is about where it was a year ago, 1¢ per sales dollar.
Since Oct 2026 the share price has risen 13%, from $981.28 to $1,105.04.
Recently
June 30, 2026
North American Pharmaceutical revenue, fiscal first quarter changed to $86.8B
Fiscal 2027 Q1 10-Q segment resultsMarch 31, 2026
Long-lived asset spending divided by revenue, fiscal year changed to 0.2%
Fiscal 2026 10-K segment dataMarch 31, 2024
Annual Property, Plant and Equipment Expenditures changed to $431.0M
McKesson Form 10-K FY2024 Statement of Cash Flows
Coming up
November 4, 2026 update expected; proposed extension through June 2032
CVS distribution agreement update
McKesson and CVS announced an agreement in principle to extend their pharmaceutical distribution partnership through June 2032; management said it would provide further updates on its next quarterly call.
McKesson Corporation Extends Pharmaceutical Distribution Agreement with CVS HealthNovember 4, 2026
Second-quarter fiscal 2027 earnings call
McKesson is scheduled to report and discuss its second-quarter results.
McKesson Corporation Investor Relations EventsMedical-Surgical Solutions separation
The planned separation remains subject to approvals and other conditions; McKesson has not stated a firm completion date in the cited annual report.
McKesson Corporation 2026 Form 10-K
Our own estimate moved too: the base case went from $766.23 to $1,149.07 a share between our last two valuations.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Customer concentration
The ten largest customers, including purchasing groups, accounted for about 73% of fiscal 2026 revenue. CVS alone accounted for about 24%, so a major change in a large customer relationship could affect sales.
From the company's own filingsWould hit how fast sales growMcKesson Corporation 2026 Form 10-K
Healthcare policy and regulation
Changes to drug pricing, public healthcare funding, and rules for pharmacy and drug distribution could change customer demand, operating costs, and the economics of distribution.
From the company's own filingsWould hit how much of each sale it keepsMcKesson Corporation 2026 Form 10-K
Legal claims involving controlled substances
McKesson faces opioid-related lawsuits and court orders governing controlled-substance distribution. Outcomes could require payments or changes to operations and may take years to resolve.
From the company's own filingsWould hit how much of each sale it keepsMcKesson Corporation 2026 Form 10-K
Planned Medical-Surgical separation
The separation may be delayed, occur on different terms, or not happen. McKesson also says the process could disrupt operations or cost more than expected.
From the company's own filingsWould hit how fast sales growMcKesson Corporation 2026 Form 10-K
Cybersecurity and system disruptions
An attack or technology outage affecting McKesson or a service provider could expose sensitive information, interrupt deliveries or services, and lead to lost customers, legal action, or added costs.
From the company's own filingsWould hit how much of each sale it keepsMcKesson Corporation 2026 Form 10-K
Strong competition
McKesson competes with large distributors and many regional and specialist providers. Customers may also build their own supply-management services, putting pressure on prices and service costs.
From the company's own filingsWould hit how much of each sale it keepsMcKesson Corporation 2026 Form 10-K
FY2025 and FY2026 exhibited higher growth of 16.22% and 12.36%, suggesting the potential for faster top-line compounding if GLP-1 indications broaden.
From our researchWould hit how fast sales growMcKesson Historical Financial Statements
Strategic acquisitions in provider practice management and oncology clinics intermittently demand incremental cash investment.
From our researchWould hit how much it has to reinvestMcKesson Form 10-K Note 3 Business Combinations
Is it a good business?
From 2017 to 2026 it earned between -478% and 2,186% on the capital invested in it, a median of 24%. Its cost of capital in the latest valuation is 6.8%; returns were above it in 4 of the 7 years.
From 2017 to 2020 it earned between 0% and 46% on its shareholders' equity, a median of 9%.
Over 10 years its operating margin ranged from 2¢ to 4¢ per sales dollar, a median of 1¢. Gross margin ran from 4¢ to 6¢.
Cost of capital 6.8%
It bought back shares: the count fell 6.2% in a year, so each remaining share owns a slightly bigger slice.
It owes $2.7B more than it holds in cash, about 0.4 years of operating profit.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $1,105.04. Our put its value between $764.42 and $1,684.78, with $1,149.07 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $764.42
This scenario models a slowdown where growth drops from recent double-digit levels to the low single digits as weight-loss drug demand cools and intense customer bargaining keeps profits slim.
Base case, $1,149.07
This scenario assumes revenue growth settles into the mid-single digits near recent quarterly trends, while profits hold steady as high-margin cancer care services balance high-volume drug deliveries.
Bull case, $1,684.78
This scenario envisions robust high-single-digit growth sustained by expanded uses for weight-loss medications, wider cancer care clinic partnerships, and expanding software profit margins.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price and our value are close.Margin of safety: 4%
For Mckesson to be worth today's $1,105.04, sales would need to grow about 5.2% a year. We assume 6.0%. Over the last 5 years, sales grew 10.8% a year.
Or, if sales grow 6.0% as we assume, the price works with a profit margin of 1.5% (we assume 1.6%).
Keep in mind: a gap this small is normal. A small change in almost any assumption would close it.
Do you think sales can grow 5.2% a year?
Try your own numbersWe're moderately sure of this range: it scores 73 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $1,149.07 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average6.0%
- Operating margin1.6%
- Long-term growth rate2.8%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$1,149.07 4.0%


